See More → 🎥 [ www.mansurfer.com/video/358262... ]
See More → 🎥 [ www.mansurfer.com/video/358262... ]
See More → 🎥 [ www.mansurfer.com/video/357642... ]
See More → 🎥 [ www.mansurfer.com/video/357642... ]
Since then: -21.1% vs. -0.1% for the S&P 500, behind the market.
https://www.insiderprint.com/ticker/HELP?utm_source=bluesky&utm_medium=social&utm_campaign=receipt
Since then: -21.1% vs. -0.1% for the S&P 500, behind the market.
https://www.insiderprint.com/ticker/HELP?utm_source=bluesky&utm_medium=social&utm_campaign=receipt
It started showing up on my Pandora channel (based on Sleigh Bells) a few months ago and i always dance like nobody's watching. 🤘
Also just found out it's a virtual artist that's actually, basically, an avatar for an art collective.
(The Cybin in me is thrilled.)
It started showing up on my Pandora channel (based on Sleigh Bells) a few months ago and i always dance like nobody's watching. 🤘
Also just found out it's a virtual artist that's actually, basically, an avatar for an art collective.
(The Cybin in me is thrilled.)
www.wholecelium.com/blog/october...
#psychedelics #octobertheory #psychonaut #wellness
www.wholecelium.com/blog/october...
#psychedelics #octobertheory #psychonaut #wellness
Ticker: $HELP
Company: Cybin D/B/A Helus Pharma
Sector: Healthcare
Industry: Biotechnology
# Employees: 100
Recent Close: $11.80
52-Week High: $15.15
52-Week High Date: 09-18-2026
% Off 52-Week High: -22.11%
52-Week Low: $3.76
Ticker: $HELP
Company: Cybin D/B/A Helus Pharma
Sector: Healthcare
Industry: Biotechnology
# Employees: 100
Recent Close: $11.80
52-Week High: $15.15
52-Week High Date: 09-18-2026
% Off 52-Week High: -22.11%
52-Week Low: $3.76
https://www.stocktitan.net/news/HELP/helus-pharma-announces-completion-of-legal-name-udn3059rwe0i.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/HELP/helus-pharma-announces-completion-of-legal-name-udn3059rwe0i.html?utm_source=stocktitan-bluesky&utm_medium=social
Chief Executive Officer Michael Halstead bought 100,000 shares at an average price of $13.47, for an estimated $1.35 million.
Chief Executive Officer Michael Halstead bought 100,000 shares at an average price of $13.47, for an estimated $1.35 million.
Cybin, now operating as Helus Pharma, is a clinical-stage pharmaceutical company developing psychedelic-based therapies for psychiatric and neurological disorders.
Cybin, now operating as Helus Pharma, is a clinical-stage pharmaceutical company developing psychedelic-based therapies for psychiatric and neurological disorders.
See More → 🎥 [ www.mansurfer.com/video/355825... ]
See More → 🎥 [ www.mansurfer.com/video/355825... ]